Skip to Content

Travere Therapeutics Inc Ordinary Shares TVTX

Morningstar Rating
$7.10 −0.23 (3.14%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TVTX is trading at a 384% premium.
Price
$7.10
Fair Value
$96.37
Uncertainty
Very High
1-Star Price
$72.62
5-Star Price
$4.84
Economic Moat
Xrw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TVTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$7.33
Day Range
$6.967.31
52-Week Range
$5.1217.73
Bid/Ask
$6.30 / $7.80
Market Cap
$540.52 Mil
Volume/Avg
976,340 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.96
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
< 0.01%

Company Profile

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
380

Comparables

Valuation

Metric
TVTX
ISEE
MORF
Price/Earnings (Normalized)
Price/Book Value
7.3011.491.97
Price/Sales
2.96
Price/Cash Flow
Price/Earnings
TVTX
ISEE
MORF

Financial Strength

Metric
TVTX
ISEE
MORF
Quick Ratio
2.6815.2437.20
Current Ratio
2.7815.5338.17
Interest Coverage
−36.28
Quick Ratio
TVTX
ISEE
MORF

Profitability

Metric
TVTX
ISEE
MORF
Return on Assets (Normalized)
−9.49%−42.04%−18.85%
Return on Equity (Normalized)
−42.23%−50.62%−19.43%
Return on Invested Capital (Normalized)
−14.33%−46.07%−23.26%
Return on Assets
TVTX
ISEE
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
GzjfrtjxHlv$629.2 Bil
Vertex Pharmaceuticals Inc
VRTX
DmyczckhDtbfkk$120.6 Bil
Regeneron Pharmaceuticals Inc
REGN
NqhtgcgbCsfkhl$114.5 Bil
Moderna Inc
MRNA
WvrdcdkrjSpc$51.1 Bil
argenx SE ADR
ARGX
JykblclqPmyj$22.7 Bil
BioNTech SE ADR
BNTX
WszwvgjfyDsftg$20.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
FwqxhfxrzPrvjl$19.5 Bil
Biomarin Pharmaceutical Inc
BMRN
DkdrmrnnFsvghv$16.0 Bil
United Therapeutics Corp
UTHR
NqcxdzxnTdt$13.6 Bil
Incyte Corp
INCY
GyxnrcrzKbzrkx$12.1 Bil

Sponsor Center